This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus Appoints Dr. Robert Schott As Vice President Of Medical Affairs

SOUTH SAN FRANCISCO, Calif., June 13, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC QB: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced that Robert J. Schott, M.D., M.P.H., F.A.C.C., has been appointed to the position of vice president of medical affairs.  Dr. Schott brings 30 years of medical experience to diaDexus, the majority as a practicing cardiologist, which will be highly relevant as the company continues to expand the market awareness of both the PLAC® Test ELISA Kit and the PLAC® Test for Lp-PLA2 Activity, simple blood tests that aid in assessing risk for coronary heart disease (CHD), ischemic stroke and cardiovascular disease. Dr. Schott most recently served as medical director and the director of cardiometabolic research at the Profil Institute for Clinical Research.

"Dr. Schott is an important addition to our leadership team.  His depth of knowledge, experience and relationships in the cardiology field will accelerate development of physician education programs necessary to drive awareness of our PLAC® blood tests. These diagnostics have a remarkable ability to help uncover a hidden risk of heart attack and stroke," stated Brian E. Ward, Ph.D., chief executive officer of diaDexus. "Dr. Schott's expertise will be instrumental not only in working closely with clinicians but also in supporting our reimbursement initiatives in order to maximize the value of our product portfolio for shareholders."

Dr. Schott joins diaDexus from San Diego where he was director of cardiometabolic research at the Profil Institute for Clinical Research, which specializes in early phase clinical research in diabetes and cardiometabolic disease. Previously, Dr. Schott was the chairman of cardiology at Deborah Heart and Lung Center, and the vice president of medical affairs and chief of cardiology at Sutter Medical Center in Sacramento. Dr. Schott holds B.S., M.D. and M.P.H. degrees from the University of Michigan, where he trained in internal medicine.  He trained in cardiology at the Massachusetts General Hospital and was a Burgher Fellow at the Harvard Medical School.  He was previously affiliated with Berkeley Heart Labs, where he was the associate director of the Lipid Institute Medical Clinic and was also a research scientist at the Max Planck Institute for Experimental Cardiology in Bad Nauheim.

"I am very enthusiastic about joining diaDexus. I have used the PLAC test as a preventive cardiologist, and have long found this marker of vascular inflammation to be clinically useful in the effort to more fully characterize heart attack and stroke risk in the growing population of patients who are susceptible to vascular events," stated Dr. Schott. "The PLAC® Test ELISA kit is FDA-approved and is recognized as a test which is well-validated as a marker for the short-term risk of heart attack and stroke. As a cardiologist who has treated thousands of patients over the years, I very much look forward to increasing our awareness of all the available tools for the detection of diseases which are increasingly manageable, diseases that when undertreated frequently have consequences that are devastating."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs